| Q89336074 | A double-blind, randomized, ascending, multiple-dose study of bazedoxifene in healthy postmenopausal women |
| Q37352516 | A new approach to menopausal therapy: the tissue selective estrogen complex |
| Q33687942 | A selective membrane estrogen receptor agonist maintains autonomic functions in hypoestrogenic states |
| Q38161857 | Advances in menopausal therapy: the tissue-selective estrogen complex |
| Q30448720 | Advances in the treatment of menopausal symptoms |
| Q37350782 | Alternatives to animal experimentation for hormonal compounds research |
| Q33780223 | An innovative method to classify SERMs based on the dynamics of estrogen receptor transcriptional activity in living animals |
| Q91136866 | Assessment of the Effects of Age and Renal Function on Pharmacokinetics of Bazedoxifene in Postmenopausal Women |
| Q38149162 | Bazedoxifene + conjugated estrogens in HT for the prevention of osteoporosis and treatment of vasomotor symptoms associated with the menopause |
| Q91738384 | Bazedoxifene Suppresses Intracellular Mycobacterium tuberculosis Growth by Enhancing Autophagy |
| Q36964723 | Bazedoxifene and bazedoxifene combined with conjugated estrogens for the management of postmenopausal osteoporosis |
| Q38734014 | Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy |
| Q42133030 | Bazedoxifene enhances the anti-tumor effects of cisplatin and radiation treatment by blocking IL-6 signaling in head and neck cancer |
| Q30413295 | Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease. |
| Q37098152 | Bazedoxifene for the prevention of postmenopausal osteoporosis |
| Q42284550 | Bazedoxifene, a selective estrogen receptor modulator, reduces cerebral aneurysm rupture in Ovariectomized rats |
| Q83774597 | Bazedoxifene: a guide to its use in postmenopausal osteoporosis |
| Q34981234 | Bazedoxifene: a new selective estrogen receptor modulator for the treatment of postmenopausal osteoporosis |
| Q37698607 | Bazedoxifene: a novel selective estrogen receptor modulator for postmenopausal osteoporosis |
| Q37950520 | Bazedoxifene: a review of its use in the treatment of postmenopausal osteoporosis |
| Q37346144 | Bazedoxifene: a selective estrogen-receptor modulator |
| Q36787639 | Bazedoxifene: a third-generation selective estrogen receptor modulator for treatment of postmenopausal osteoporosis |
| Q34213748 | Bazedoxifene: literature data and clinical evidence |
| Q36059535 | Bazedoxifene: the evolving role of third-generation selective estrogen-receptor modulators in the management of postmenopausal osteoporosis |
| Q88528893 | Blocking IL-6/GP130 Signaling Inhibits Cell Viability/Proliferation, Glycolysis, and Colony Forming Activity in Human Pancreatic Cancer Cells |
| Q47104711 | Blocking interleukin-6 signaling inhibits cell viability/proliferation, glycolysis, and colony forming activity of human medulloblastoma cells |
| Q30409045 | Breast-related effects of selective estrogen receptor modulators and tissue-selective estrogen complexes |
| Q37676345 | Conjugated estrogens and bazedoxifene |
| Q38192058 | Conjugated estrogens combined with bazedoxifene: the first approved tissue selective estrogen complex therapy |
| Q36548722 | Developments in the pharmacotherapeutic management of osteoporosis |
| Q43042884 | Disposition of bazedoxifene in rats |
| Q37146858 | Effects of bazedoxifene acetate with and without conjugated equine estrogens on the breast of postmenopausal monkeys |
| Q35285821 | Effects of lasofoxifene and bazedoxifene on B cell development and function |
| Q30380010 | Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidence |
| Q35092811 | Efficacy and safety of bazedoxifene for postmenopausal osteoporosis |
| Q46110515 | Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial |
| Q36944034 | Emerging pharmacologic therapies for osteoporosis |
| Q37483322 | Endometrial profile of bazedoxifene acetate alone and in combination with conjugated equine estrogens in a primate model |
| Q33638802 | Endometrial profile of tamoxifen and low-dose estradiol combination therapy |
| Q30447470 | Estrogen agonists/antagonists in combination with estrogen for prevention and treatment of menopause-associated signs and symptoms |
| Q92144294 | Estrogen-SIRT1 Axis Plays a Pivotal Role in Protecting Arteries Against Menopause-Induced Senescence and Atherosclerosis |
| Q34484414 | Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader. |
| Q38077503 | Evolution of the tissue selective estrogen complex (TSEC). |
| Q34315413 | From empirical to mechanism-based discovery of clinically useful Selective Estrogen Receptor Modulators (SERMs). |
| Q43715217 | Global profiling of TSEC proliferative potential by the use of a reporter mouse for proliferation. |
| Q37633123 | Gq-mER signaling has opposite effects on hypothalamic orexigenic and anorexigenic neurons |
| Q37781651 | Hot flushes: are there effective alternatives to estrogen? |
| Q35092609 | Incorporating bazedoxifene into the treatment paradigm for postmenopausal osteoporosis in Japan |
| Q35885187 | Incorporating bazedoxifene/conjugated estrogens into the current paradigm of menopausal therapy |
| Q36745212 | Membrane-initiated actions of estradiol that regulate reproduction, energy balance and body temperature |
| Q33347137 | Metabolic actions of estrogen receptor beta (ERbeta) are mediated by a negative cross-talk with PPARgamma |
| Q26860081 | Minireview: neural signaling of estradiol in the hypothalamus |
| Q33346629 | Molecular analysis of the vaginal response to estrogens in the ovariectomized rat and postmenopausal woman |
| Q34335027 | Muscle GLUT4 regulation by estrogen receptors ERbeta and ERalpha |
| Q27014775 | New antiresorptive therapies for postmenopausal osteoporosis |
| Q38616755 | New management options for osteoporosis with emphasis on SERMs |
| Q36532562 | Novel targets and therapeutics for bone loss. |
| Q26825692 | Nuclear receptors and their selective pharmacologic modulators |
| Q97527813 | Pharmacokinetic comparison of two bazedoxifene acetate 20 mg tablet formulations in healthy Korean male volunteers |
| Q38102040 | Pharmacokinetic evaluation of bazedoxifene for the treatment of osteoporosis. |
| Q50005305 | Pharmacokinetics and Safety of Bazedoxifene in Hepatically Impaired and Healthy Postmenopausal Women |
| Q37156496 | Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer |
| Q27650591 | Prediction of the tissue-specificity of selective estrogen receptor modulators by using a single biochemical method |
| Q37048294 | Profile of bazedoxifene/conjugated estrogens for the treatment of estrogen deficiency symptoms and osteoporosis in women at risk of fracture |
| Q38129004 | Profile of ospemifene in the breast |
| Q26851890 | Progress in the molecular understanding of central regulation of body weight by estrogens |
| Q40344336 | Protective effects of bazedoxifene paired with conjugated estrogens on pancreatic β-cell dysfunction |
| Q33866426 | Repositioning Bazedoxifene as a novel IL-6/GP130 signaling antagonist for human rhabdomyosarcoma therapy |
| Q36065502 | Research resource: Transcriptional profiling in a cellular model of breast cancer reveals functional and mechanistic differences between clinically relevant SERM and between SERM/estrogen complexes |
| Q37743272 | SERMs and SERMs with estrogen for postmenopausal osteoporosis |
| Q37070860 | SERMs have substance-specific effects on bone, and these effects are mediated via ERαAF-1 in female mice |
| Q33613016 | Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis |
| Q55042739 | Selective estrogen receptor modulators (SERMS). |
| Q34490225 | Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast |
| Q36822378 | Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development |
| Q38455538 | Selective estrogen receptor modulators in clinical practice: a safety overview |
| Q34134828 | Selective estrogen receptor modulators: tissue specificity and clinical utility |
| Q43803456 | Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study |
| Q64946029 | The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells. |
| Q48189748 | The Tissue-Selective Estrogen Complex (Bazedoxifene/Conjugated Estrogens) for the Treatment of Menopause. |
| Q26830744 | The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice |
| Q35646553 | The effects of 17β-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis |
| Q87450610 | The effects of bazedoxifene in the ovariectomized aged cynomolgus monkey |
| Q37631061 | The endometrium--from estrogens alone to TSECs |
| Q26827973 | The evolution of selective estrogen receptor modulators in osteoporosis therapy |
| Q35275278 | The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor α and cyclin D1. |
| Q37277298 | The tissue selective estrogen complex: a promising new menopausal therapy |
| Q53837780 | Tissue selective estrogen complex (TSEC): a review. |
| Q37304372 | Tissue selective estrogen complexes (TSECs) differentially modulate markers of proliferation and differentiation in endometrial cells. |
| Q37801227 | Tissue-Selective Agents: Selective Estrogen Receptor Modulators and the Tissue-Selective Estrogen Complex |
| Q30454254 | Tissue-selective estrogen complex bazedoxifene and conjugated estrogens for the treatment of menopausal vasomotor symptoms |
| Q37636428 | Tissue-selective estrogen complexes with bazedoxifene prevent metabolic dysfunction in female mice. |
| Q37768158 | Tissue-selective estrogen complexes: a promising option for the comprehensive management of menopausal symptoms |
| Q34271979 | Treating postmenopausal osteoporosis in women at increased risk of fracture - critical appraisal of bazedoxifene: a review |
| Q28258998 | Update on bazedoxifene: a novel selective estrogen receptor modulator |